HK1111888A1 - Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2- yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide n-[5-()-4--13--2-]-n--2-[4-(2-)] - Google Patents

Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2- yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide n-[5-()-4--13--2-]-n--2-[4-(2-)]

Info

Publication number
HK1111888A1
HK1111888A1 HK08106516.4A HK08106516A HK1111888A1 HK 1111888 A1 HK1111888 A1 HK 1111888A1 HK 08106516 A HK08106516 A HK 08106516A HK 1111888 A1 HK1111888 A1 HK 1111888A1
Authority
HK
Hong Kong
Prior art keywords
methyl
aminosulfonyl
thiazol
pyridinyl
acetamide
Prior art date
Application number
HK08106516.4A
Other languages
English (en)
Chinese (zh)
Inventor
Tobias Laich
Katrin Liebelt
Original Assignee
艾庫里斯有限及兩合公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾庫里斯有限及兩合公司 filed Critical 艾庫里斯有限及兩合公司
Publication of HK1111888A1 publication Critical patent/HK1111888A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK08106516.4A 2005-03-30 2008-06-12 Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2- yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide n-[5-()-4--13--2-]-n--2-[4-(2-)] HK1111888A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005014248A DE102005014248A1 (de) 2005-03-30 2005-03-30 Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
PCT/EP2006/002566 WO2006103011A1 (de) 2005-03-30 2006-03-21 Pharmazeutische zubereitung von n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamid

Publications (1)

Publication Number Publication Date
HK1111888A1 true HK1111888A1 (en) 2008-08-22

Family

ID=36608733

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08106516.4A HK1111888A1 (en) 2005-03-30 2008-06-12 Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2- yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide n-[5-()-4--13--2-]-n--2-[4-(2-)]

Country Status (11)

Country Link
US (1) US8784887B2 (pt)
EP (1) EP1865921B1 (pt)
JP (1) JP5086989B2 (pt)
CN (1) CN101151019B (pt)
AU (1) AU2006228747B2 (pt)
BR (1) BRPI0612188B8 (pt)
CA (1) CA2602750C (pt)
DE (1) DE102005014248A1 (pt)
HK (1) HK1111888A1 (pt)
IL (1) IL185759A0 (pt)
WO (1) WO2006103011A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
EP2573086A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
JP2016507546A (ja) * 2013-02-12 2016-03-10 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト アルツハイマー病を治療する方法において使用するためのヘリカーゼ／プライマーゼ阻害剤
MY198018A (en) 2016-04-06 2023-07-26 Lnnovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
HUE054845T2 (hu) * 2016-11-28 2021-10-28 Aicuris Gmbh & Co Kg Az N-[5-(amino-szulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamid szabad bázis maleát sója, gyógyászati készítmények, elõállítási eljárások és Herpes vírusok kezelésére történõ alkalmazások
WO2018095576A1 (en) 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh Topical pharmaceutical formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide
DK3544976T3 (da) * 2016-11-28 2021-05-10 Aicuris Gmbh & Co Kg N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf
EP3566749A4 (en) * 2017-01-09 2020-09-23 Medshine Discovery Inc. THIAZOLE DERIVATIVE AND USES OF IT
UA126076C2 (uk) 2017-06-28 2022-08-10 Айкуріс Ґмбг Унд Ко. Кґ Пристрій для інтравагінального введення прителівіру
SI3692039T1 (sl) 2017-10-05 2023-04-28 Innovative Molecules Gmbh Enantomeri substituiranih tiazolov kot protivirusne spojine
AU2019297214B2 (en) * 2018-07-06 2022-07-07 Phaeno Therapeutics Co., Ltd. Crystal forms of thiazole compound and application thereof
EP3925595A1 (en) 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
KR20220160024A (ko) 2020-03-26 2022-12-05 아이쿠리스 게엠베하 운트 코. 카게 N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 반수화물을 포함하는 안과용 제제
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA984848A (en) 1970-01-16 1976-03-02 Kurt H. Pilgram Herbicides
US3658830A (en) * 1970-01-16 1972-04-25 Shell Oil Co 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl)
US3847588A (en) * 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
US3717651A (en) * 1970-04-20 1973-02-20 Shell Oil Co Thiazoles
GB2080682B (en) * 1980-07-30 1984-03-28 Ciba Geigy Ag Antiherpetically active lipstick
US4556560A (en) * 1983-01-24 1985-12-03 The Procter & Gamble Company Methods for the treatment and prophylaxis of diaper rash and diaper dermatitis
DE3319282A1 (de) * 1983-05-27 1984-11-29 Gödecke AG, 1000 Berlin Verwendung von adenosin bei der behandlung von herpes
WO1997024343A1 (en) 1995-12-29 1997-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Phenyl thiazole derivatives with anti herpes virus properties
GB2311069A (en) 1996-03-14 1997-09-17 Merck & Co Inc Primase isolated from human cytomegalovirus (HCMV)
US5705344A (en) 1996-03-14 1998-01-06 Tularik, Inc. High-throughput screening assay for inhibitors of nucleic acid helicases
GB2311068A (en) 1996-03-14 1997-09-17 Merck & Co Inc Helicase isolated from human cytomegalovirus (HCMV)
CA2223032A1 (en) 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
AU743489B2 (en) 1998-03-19 2002-01-24 Pharmacia & Upjohn Company 1,3,4-thiadiazoles useful for the treatment of CMV infections
ES2559766T3 (es) * 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
AU2914200A (en) 1999-03-08 2000-09-28 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
AU2000259734A1 (en) 2000-06-15 2001-12-24 Gerald Kleymann Method for identifying compounds with anti-herpes activity
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
JP2007524596A (ja) * 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物

Also Published As

Publication number Publication date
JP2008534539A (ja) 2008-08-28
AU2006228747A1 (en) 2006-10-05
EP1865921A1 (de) 2007-12-19
CA2602750A1 (en) 2006-10-05
EP1865921B1 (de) 2013-12-04
BRPI0612188B1 (pt) 2020-05-05
JP5086989B2 (ja) 2012-11-28
WO2006103011A1 (de) 2006-10-05
AU2006228747B2 (en) 2011-11-03
CA2602750C (en) 2013-11-19
BRPI0612188A2 (pt) 2010-10-26
US20080220059A1 (en) 2008-09-11
CN101151019A (zh) 2008-03-26
DE102005014248A1 (de) 2006-10-05
US8784887B2 (en) 2014-07-22
CN101151019B (zh) 2011-08-31
IL185759A0 (en) 2008-01-06
BRPI0612188B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HK1111888A1 (en) Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2- yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide n-[5-()-4--13--2-]-n--2-[4-(2-)]
EP2602258B8 (en) N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
MX2014003623A (es) Monohidrato de mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol -2-il]-2-[4-(2-piridinil)-fenil]-n-metilacetamida con un intervalo de distribucion de tamaño de particula especifica y un intervalo de area superficial especifica para uso en formulaciones farmaceuticas.
IL202018A (en) 4,2-Difluoro-n- {2- (Methylaoxy) -5- [4- (4-Pyridazinyl) -6-Quinolinyl] -3-Pyridinyl} Benzenesulfonamide, its Pharmaceuticals and Its Use in the Treatment of Pi3 Kinase-Related Diseases
UA92349C2 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
NO20090834L (no) Anvendelse av azabicykloheksanderivater
IL206470A (en) 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
RS61905B1 (sr) Hemihidrat slobodne baze n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida, postupci njegove proizvodnje i upotrebe
PT3544977T (pt) Um sal maleato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulações farmacêuticas, métodos de produção e suas utilizações para o tratamento de vírus herpes
CL2007001692A1 (es) Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina.
HUP0600347A3 (en) Process for the preparation of {2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one (ziprasidon) and the intermediate
PT2602258E (pt) Monohidrato de mesilato de n-[5-aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida
IL199822A0 (en) Sealed package of pharmaceutical composition comprising 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy] phenyl] methyl]-2,4-thiazolidinedione)butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
BR112014003246A2 (pt) ácido n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]acetamida monometanossulfônico monohidratado cristalino e composição farmacêutica contendo partículas do mesmo
AU2003269483A1 (en) Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
JP2014520147A5 (pt)
IL193682A0 (en) Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl)2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide, sodium salt